Trial Profile
Phase II Trial of EPOCH and Rituxan Combined Therapy in Patients With Refractory or Relapsed CD20 Positive Intermediate Grade B-Cell Non-Hodgkin's Lymphoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 19 Oct 2021 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 13 Sep 2005 New trial record.